Intermittent Versus Continuous HAART (Highly Active Antiretroviral Therapy) for Treating Chronic HIV Infected Patients in Uganda
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00339456|
Recruitment Status : Completed
First Posted : June 21, 2006
Last Update Posted : April 19, 2018
|Condition or disease||Intervention/treatment||Phase|
|HIV||Drug: HAART||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||155 participants|
|Official Title:||A Randomized, Controlled Trial of Short Cycle Intermittent Versus Continuous HAART for the Treatment of Chronic HIV Infection in Uganda|
|Study Start Date :||August 21, 2002|
|Actual Primary Completion Date :||February 1, 2008|
|Actual Study Completion Date :||February 1, 2008|
- To evaluate the effects of short cycle intermittent versus continuous HAART on viral load.
- To evaluate change in CD4 T-cell counts, change in virus patterns, toxicity and side effects, Quality of Life, and adherence.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00339456
|Joint Clinical Research Center|
|Principal Investigator:||Thomas C Quinn, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|